THE RESULTS OF PALIVIZUMAB USAGE IN NEWBORNS AT RISK FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS DEVELOPMENT
Respiratory syncytial virus (RSV) accounts for a great part among the structure of ARVI morbidity. There is an international practice to use immune-prevention programs for RSV and to arrange hygienic procedures, all these leading to reduction of infant mortality rate and frequency of hospitalization of children from risk group for severe RSV. For the first time Ufa has started an immune-prevention program for RSV among children from high risk group for severe diseases of lower respiratory tract in epidemic season 2012-2013.The study examined 96 preterm newborns admitted to the NICU GDKB number 17 in 2012 and 2013. Preterm infants with RDS, complicated by pneumonia, children with BPD and hemodynamically significant functioning arterial duct were injected the drug Palivizumab before transferring from the intensive care unit and neonatal intensive care to the further stage or before discharge from the Department of Pathology of Newborns. As a result it was stated that passive immunisation with the drug Palivizumab of the premature infants with RDS, complicated by pneumonia, BPD and hemodynamically significant functioning arterial duct led to the decrease of repeated hospitalization of these patients into the pediatric unit (hospital) and infant mortality rate.